Three of the best biotech stocks to buy now

Biotechnology firms are benefiting from demand from ageing populations. But as Dr Daniel Koller explains, there’s more to the biotech boom than that.

Each week, a professional investor tells MoneyWeek where he'd put his money now. This week:Dr Daniel Koller, lead manager of BB Biotech, Bellevue Asset Management.

Biotechnology firms are benefiting from rising demand for health-care products from ageing populations, and from increasingly health-conscious emerging markets. But there's more to the biotech boom than that.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Dr Daniel Koller is head of BB Biotech at Bellevue Asset Management and resides in Zurich, Switzerland. He occasionally writes for MoneyWeek online and print and gives his share tips.